Denosumab in postmenopausal women with low bone mineral density.
Open accessThe DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Receptor activator of nuclear factor-kappaB ligand (RANKL) is essential for osteoclast differentiation, activation, and survival. The fully human monoclonal antibody denosumab (formerly known as AMG 162) binds RANKL with high affinity and specificity and inhibits RANKL action. METHODS: The efficacy and safety of subcutaneously administered denosumab were evaluated over a period of 12 months in 412 postmenopausal women with low bone mineral density (T score of -1.8 to -4.0 at the lumbar spine or -1.8 to -3.5 at the proximal femur). Subjects were randomly assigned to receive denosumab either every three months (at a dose of 6, 14, or 30 mg) or every six months (at a dose of 14, 60, 100, or 210 mg), open-label oral alendronate once weekly (at a dose of 70 mg), or placebo. The primary end point was the percentage change from baseline in bone mineral density at the lumbar spine at 12 months. Changes in bone turnover were assessed by measurement of serum and urine telopeptides and bone-specific alkaline phosphatase. RESULTS: Denosumab treatment for 12 months resulted in an increase in bone mineral density at the lumbar spine of 3.0 to 6.7 percent (as compared with an increase of 4.6 percent with alendronate and a loss of 0.8 percent with placebo), at the total hip of 1.9 to 3.6 percent (as compared with an increase of 2.1 percent with alendronate and a loss of 0.6 percent with placebo), and at the distal third of the radius of 0.4 to 1.3 percent (as compared with decreases of 0.5 percent with alendronate and 2.0 percent with placebo). Near-maximal reductions in mean levels of serum C-telopeptide from baseline were evident three days after the administration of denosumab. The duration of the suppression of bone turnover appeared to be dose-dependent. CONCLUSIONS: In postmenopausal women with low bone mass, denosumab increased bone mineral density and decreased bone resorption. These preliminary data suggest that denosumab might be an effective treatment for osteoporosis. (ClinicalTrials.gov number, NCT00043186.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Denosumab administration in postmenopausal women with low BMD resulted in gains in BMD at the total hip, femoral neck, and distal radius at 12 and 24 months (230).”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [230]
In the citing paper
“at the total hip of 1.9 to 3.6% (vs.an increase of 2% with alendronate and a loss of 0.6% with placebo)”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [230]
In the citing paper
“Treatment with denosumab resulted in a mean increase in BMD at the lumbar spine of 3.0 to 6.7% (vs.an increase of 4.6% with alendronate and a loss of 0.8% with placebo)”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [230]
In the citing paper
“Those gains in BMD were associated with decreases in bone resorption.”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [230]
In the citing paper
“and at the distal third of the radius of 0.4 to 1.3% (vs.decreases of 0.5% with alendronate and 2.0% with placebo).”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [230]
Citations
Cites
An analysis of variance test for normality (complete samples)
SHAPIRO, S. S., & WILK, M. B. (1965) · Biometrika · doi:10.1093/biomet/52.3-4.591 · Cited by 23,480
Prediction of Creatinine Clearance from Serum Creatinine
Cockcroft, D. W., & Gault, H. (1976) · Nephron · doi:10.1159/000180580 · Cited by 15,309
Osteoporosis Prevention, Diagnosis, and Therapy
NIH Consensus Development Panel on Osteoporosis Prevention, D. (2001) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.285.6.785 · Cited by 5,529
Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation.
Lacey, D. L., Timms, E., Tan, H.-L., Kelley, M. J., Dunstan, C. R., Burgess, T., Elliott, R., Colombero, A., Elliott, G., Scully, S., et al. (1998) · Cell · doi:10.1016/s0092-8674(00)81569-x · Cited by 5,439
Osteoprotegerin: a novel secreted protein involved in the regulation of bone density.
Simonet, W. S., Lacey, D. L., Dunstan, C. R., Kelley, M., Chang, M.-S., Lüthy, R., Nguyen, H. Q., Wooden, S., Bennett, L., Boone, T., et al. (1997) · Cell · doi:10.1016/s0092-8674(00)80209-3 · Cited by 5,130
A sharper Bonferroni procedure for multiple tests of significance
HOCHBERG, Y. (1988) · Biometrika · doi:10.1093/biomet/75.4.800 · Cited by 4,829
Yasuda, H., Shima, N., Nakagawa, N., Yamaguchi, K., Kinosaki, M., Mochizuki, S.-I., Tomoyasu, A., Yano, K., Goto, M., Murakami, A., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.7.3597 · Cited by 4,228
Hsu, H., Lacey, D. L., Dunstan, C. R., Solovyev, I., Colombero, A., Timms, E., Tan, H.-L., Elliott, G., Kelley, M. J., Sarosi, I., et al. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.7.3540 · Cited by 1,636
Bekker, P. J., Holloway, D. L., Rasmussen, A. S., Murphy, R., Martin, S. W., Leese, P. T., Holmes, G. B., Dunstan, C. R., & DePaoli, A. M. (2004) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.040305 · Cited by 771
Self-citationThe ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts.
Burgess, T. L., Qian, Y.-X., Kaufman, S., Ring, B. D., Van, G., Capparelli, C., Kelley, M., Hsu, H., Boyle, W. J., Dunstan, C. R., et al. (1999) · The Journal of Cell Biology · doi:10.1083/jcb.145.3.527 · Cited by 689
Research works printed but not linked: 3
- Schroeder K, 2004, Cochrane Database Syst Rev, 2, CD004804
- van Elteren PH, 1960, Bull Int Stat Inst, 37, 351
- Schnitzer T, 2000, Aging (Milano), 12, 1
Cited by
Items 401–500 of 1,000
4-PBA Treatment Improves Bone Phenotypes in the Aga2 Mouse Model of Osteogenesis Imperfecta
Durán, I., Zieba, J. T., Csukasi, F., Martin, J. H., Wachtell, D., Barad, M., Dawson, B., Fafílek, B., Jacobsen, C. M., Ambrose, C. G., et al. (2020) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.4501 · Cited by 40
Miller, P. D., & Derman, R. J. (2010) · Osteoporosis International · doi:10.1007/s00198-010-1208-3 · Cited by 41
Self-citationThe molecular pathogenesis of Paget disease of bone
Layfield, R. (2007) · Expert Reviews in Molecular Medicine · doi:10.1017/s1462399407000464 · Cited by 39
Osteoporosis in the aging male: Treatment options
Tuck (2008) · Clinical Interventions in Aging · doi:10.2147/cia.s820 · Cited by 39
Rizzoli, R., Benhamou, C.-L., Halse, J., Miller, P. D., Reid, I. R., Rodríguez Portales, J. A., DaSilva, C., Kroon, R., Verbruggen, N., Leung, A. T., et al. (2016) · Osteoporosis International · doi:10.1007/s00198-016-3503-0 · Cited by 39
Self-citationZhu, Y., Huang, Z., Wang, Y., Xu, W., Chen, H., Xu, J., Luo, S., Zhang, Y., Zhao, D., & Hu, J. (2019) · Journal of Orthopaedic Translation · doi:10.1016/j.jot.2019.08.004 · Cited by 38
Hao, X., Chang, J., Qin, B., Zhong, C., Chu, Z., Huang, J. Y., Zhou, W., & Sun, X. (2015) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2015.07.042 · Cited by 38
Emerging treatments for postmenopausal osteoporosis – focus on denosumab
Geusens, P. (2009) · Clinical Interventions in Aging · doi:10.2147/cia.s3333 · Cited by 44
Toll gates to periodontal host modulation and vaccine therapy
Hajishengallis, G. (2009) · Periodontology 2000 · doi:10.1111/j.1600-0757.2009.00304.x · Cited by 38
Denosumab: A Review of its Use in Postmenopausal Women with Osteoporosis
Scott, L. J. (2014) · Drugs & Aging · doi:10.1007/s40266-014-0191-3 · Cited by 37
Chandran, T., & Venkatachalam, I. (2019) · Singapore Medical Journal · doi:10.11622/smedj.2019028 · Cited by 37
Pedersen, A. B., Heide‐Jørgensen, U., Sørensen, H. T., Prieto‐Alhambra, D., & Ehrenstein, V. (2019) · JAMA Network Open · doi:10.1001/jamanetworkopen.2019.2416 · Cited by 39
RANK(L) as a Key Target for Controlling Bone Loss
Leibbrandt, A., & Penninger, J. M. (2009) · Advances in experimental medicine and biology · doi:10.1007/978-0-387-89520-8_9 · Cited by 39
Role of osteoclasts in regulating hematopoietic stem and progenitor cells
Miyamoto, T. K. (2013) · World Journal of Orthopedics · doi:10.5312/wjo.v4.i4.198 · Cited by 44
RANKL inhibition for the management of patients with benign metabolic bone disorders
Anastasilakis, A. D., Toulis, K. A., Pοlyzos, S. A., & Terpos, E. (2009) · Expert Opinion on Investigational Drugs · doi:10.1517/13543780903048929 · Cited by 38
Kumar, S., Gild, M., Mcdonald, M., Kim, A. S., Clifton-Bligh, R., & Girgis, C. (2024) · Osteoporosis International · doi:10.1007/s00198-024-07139-9 · Cited by 33
Denosumab for osteoporosis treatment: when, how, for whom, and for how long. A pragmatical approach
Lamy, O., Everts‐Graber, J., & Rodríguez, E. G. (2025) · Aging Clinical and Experimental Research · doi:10.1007/s40520-025-02991-z · Cited by 37
2011 Up-Date of the Consensus Statement of the Spanish Society of Rheumatology on Osteoporosis
Pérez-Edo, L., Ruiz, A. A., Vilaseca, D. R., García-Vadillo, A., Gay, N. G., Peris, P., Eslava, A. T., Audera, C. B., Aresté, J. F., Rodríguez, L. M. A., et al. (2011) · Reumatología Clínica (English Edition) · doi:10.1016/j.reumae.2011.05.007 · Cited by 45
Denosumab for the treatment of osteoporosis
McClung, M. R. (2017) · Osteoporosis and Sarcopenia · doi:10.1016/j.afos.2017.01.002 · Cited by 39
Self-citationSeeto, A. H., Abrahamsen, B., Ebeling, P. R., & Rodríguez, A. J. (2020) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.4157 · Cited by 39
Novel insights on the effect of sclerostin on bone and other organs
Dreyer, T. J., Keen, J. A. C., Wells, L. M., & Roberts, S. J. (2023) · Journal of Endocrinology · doi:10.1530/joe-22-0209 · Cited by 38
Karsdal, M. A., Qvist, P., Christiansen, C., & Tank, L. S. B. (2006) · Drugs · doi:10.2165/00003495-200666150-00002 · Cited by 40
Morrissey, C. M., Kostenuik, P. J., Brown, L. G., Vessella, R. L., & Corey, E. (2007) · BMC Cancer · doi:10.1186/1471-2407-7-148 · Cited by 36
Serum osteoprotegerin levels and long-term prognosis in patients with stable angina pectoris
Pedersen, E. R., Ueland, T., Seifert, R., Aukrust, P., Schartum-Hansen, H., Ebbing, M., Bleie, Ø., Igland, J., Svingen, G. F. T., Nordrehaug, J. E., et al. (2010) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2010.06.027 · Cited by 36
Anti-RANKL therapy for bone tumours: Basic, pre-clinical and clinical evidences
Heymann, D. (2012) · Journal of bone oncology · doi:10.1016/j.jbo.2012.03.001 · Cited by 38
Pοlyzos, S. A., Singhellakis, P. N., Naot, D., Adamidou, F., Malandrinou, F. C., Anastasilakis, A. D., Polymerou, V., & Kita, M. D. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-3762 · Cited by 41
Effects of Denosumab on Bone Mineral Density and Bone Turnover in Postmenopausal Women
Wensel, T. M., Iranikhah, M., & Wilborn, T. W. (2011) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.31.5.510 · Cited by 36
Biochemical Markers of Bone Metabolism
Cremers, S., Garnero, P., & Seibel, M. J. (2008) · Elsevier eBooks · doi:10.1016/b978-0-12-373884-4.00020-3 · Cited by 57
OPG/RANKL/RANK Pathway as a Therapeutic Target in Cancer
McGrath, E. E. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318229421f · Cited by 39
DeLuca, H. F., Bedale, W. A., Binkley, N., Gallagher, J. C., Bolognese, M. A., Peacock, M., Aloia, J. F., Clagett‐Dame, M., & Plum, L. A. (2010) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.256 · Cited by 35
Self-citationApplication of Quantitative Pharmacology in Development of Therapeutic Monoclonal Antibodies
Tabrizi, M. A., Funelas, C. B., & Suria, H. (2010) · The AAPS Journal · doi:10.1208/s12248-010-9220-2 · Cited by 36
Zhang, J., Redden, D. T., McGwin, G., Callahan, L. F., Smith, E. A., Alarcón, G. S., Moreland, L. W., van der Heijde, D. M. F. M., Brown, E. E., Arnett, D. K., et al. (2010) · Arthritis & Rheumatism · doi:10.1002/art.27510 · Cited by 35
McClung, M. R., Zanchetta, J., Høiseth, A. D., Kendler, D. L., Yuen, C. K., Brown, J. P., Stonkus, S., Goemaere, S., Recknor, C. P., Woodson, G. C., et al. (2012) · Journal of Clinical Densitometry · doi:10.1016/j.jocd.2012.02.014 · Cited by 35
Self-citationDevelopments in the pharmacotherapeutic management of osteoporosis
Close, P., Neuprez, A., & Reginster, J. (2006) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.7.12.1603 · Cited by 40
Kumagai, Y., Hasunuma, T., & Padhi, D. (2011) · Bone · doi:10.1016/j.bone.2011.08.007 · Cited by 34
Hoyer‐Kuhn, H., Rehberg, M., Netzer, C., Schöenau, E., & Semler, O. (2019) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-019-1197-z · Cited by 34
Advances in Osteoimmunology: Pathophysiologic Concepts and Treatment Opportunities
Rauner, M., Sipos, W., Thiele, S., & Pietschmann, P. (2012) · International Archives of Allergy and Immunology · doi:10.1159/000342426 · Cited by 35
Pathophysiology of age-related diseases
Campisi, G., Chiappelli, M., Martinis, M. D., Franco, V., Ginaldi, L., Guiglia, R., Licastro, F., & Lio, D. (2009) · Immunity & Ageing · doi:10.1186/1742-4933-6-12 · Cited by 36
Hd, N., Em, H., Chou, R., Dana, T., Fu, R., & Bougatsos, C. (2010) · Europe PMC (PubMed Central) · Cited by 45
Kobayashi, T., Morimoto, T., Ito, K., Mawatari, M., & Shimazaki, T. (2024) · Osteoporosis International · doi:10.1007/s00198-024-07118-0 · Cited by 35
Preventing osteoporosis in symptomatic postmenopausal women
Gallagher, J. C., & Levine, J. P. (2010) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0b013e3181e324a6 · Cited by 34
Eller-Vainicher, C. (2016) · Clinical cases in mineral and bone metabolism · doi:10.11138/ccmbm/2016.13.3.253 · Cited by 33
Sharma, A., Sharma, L. K., & Goyal, R. (2020) · Current Drug Targets · doi:10.2174/1389450121666200910160404 · Cited by 39
Iolascon, G., Napolano, R., Gioia, M., Moretti, A., Riccio, I., & Gimigliano, F. (2013) · Clinical cases in mineral and bone metabolism · doi:10.11138/ccmbm/2013.10.1.047 · Cited by 47
Novel targets in bone and cartilage
Beyer, C., & Schett, G. A. (2010) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2010.03.001 · Cited by 35
Denosumab: recent update in postmenopausal osteoporosis.
da Silva, I. S., & Branco, J. (2012) · PubMed · Cited by 35
Narducci, P., Bareggi, R., & Nicolin, V. (2009) · Acta Histochemica · doi:10.1016/j.acthis.2009.10.003 · Cited by 37
Prevention and treatment of bone fragility in cancer patient
Ottanelli, S. (2015) · Clinical cases in mineral and bone metabolism · doi:10.11138/ccmbm/2015.12.2.116 · Cited by 35
Unexpected Bone Formation Produced by RANKL Blockade
Portal-Núñez, S., Mediero, A., Esbrit, P., Sánchez-Pernaute, O., Largo, R., & Herrero-Beaumont, G. (2017) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2017.06.003 · Cited by 32
Everts‐Graber, J., Bonél, H., Lehmann, D., Gahl, B., Häuselmann, H., Studer, U., Ziswiler, H., Reichenbach, S., & Lehmann, T. (2023) · Osteoporosis International · doi:10.1007/s00198-023-06863-y · Cited by 32
Sawamura, M., Komatsuda, A., Togashi, M., Wakui, H., & Takahashi, N. (2017) · Internal Medicine · doi:10.2169/internalmedicine.56.7797 · Cited by 32
Akiyama, T., Dass, C. R., Shinoda, Y., Kawano, H., Tanaka, S., & Choong, P. (2010) · Journal of Pharmacy and Pharmacology · doi:10.1211/jpp.62.04.0009 · Cited by 33
OPG/RANKL: Implication et cible thérapeutique dans l’ostéoporose
Marie, P. J., & Halbout, P. (2008) · médecine/sciences · doi:10.1051/medsci/2008241105 · Cited by 38
Therapeutic intervention for wear debris-induced aseptic implant loosening
Ren, K., Dusad, A., Zhang, Y., & Wang, D. (2013) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2013.02.005 · Cited by 32
Skeletal deterioration induced by RANKL infusion: a model for high-turnover bone disease
Yuan, Y. Y., Kostenuik, P. J., Ominsky, M. S., Morony, S., Adamu, S., Simionescu, D. T., Basalyga, D. M., Asuncion, F., & Bateman, T. A. (2007) · Osteoporosis International · doi:10.1007/s00198-007-0509-7 · Cited by 33
Villa, J. C., Gianakos, A. L., & Lane, J. M. (2015) · HSS Journal® The Musculoskeletal Journal of Hospital for Special Surgery · doi:10.1007/s11420-015-9469-1 · Cited by 38
Lorenzo‐Pouso, A. I., Pérez‐Sayáns, M., González‐Palanca, S., Chamorro-Petronacci, C. M., Sebastián, J. V. B., & García, A. G. (2018) · Medicina oral, patología oral y cirugía bucal · doi:10.4317/medoral.22763 · Cited by 40
Fatal attraction: why breast cancer cells home to bone
Hofbauer, L. C., Rachner, T. D., & Singh, S. K. (2008) · Breast Cancer Research · doi:10.1186/bcr1848 · Cited by 36
Giant Cell Tumor of Bone in Childhood: Clinical Aspects and Novel Therapeutic Targets
Federman, N. C., Brien, E. W., Narasimhan, V., Dry, S., Sodhi, M., & Chawla, S. P. (2013) · Pediatric Drugs · doi:10.1007/s40272-013-0051-3 · Cited by 31
Effects of denosumab on bone density, mass and strength in women with postmenopausal osteoporosis
Törring, O. (2015) · Therapeutic Advances in Musculoskeletal Disease · doi:10.1177/1759720x15579189 · Cited by 31
Soluble Rank Ligand Produced by Myeloma Cells Causes Generalised Bone Loss in Multiple Myeloma
Buckle, C., Leenheer, E. D., Lawson, M. A., Yong, K., Rabin, N. K., Perry, M., Vanderkerken, K., & Croucher, P. I. (2012) · PLoS ONE · doi:10.1371/journal.pone.0041127 · Cited by 34
Iranikhah, M., Wilborn, T. W., Wensel, T. M., & Ferrell, J. B. (2012) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/j.1875-9114.2011.01092.x · Cited by 34
Denosumab: an investigational drug for the management of postmenopausal osteoporosis
Lewiecki, M. E. (2008) · Biologics · doi:10.2147/btt.s2082 · Cited by 37
Denosumab-related osteonecrosis of the jaw: a case report and management based on pharmacokinetics
You, T. M., Lee, K.-H., Lee, S. H., & Park, W. (2015) · Oral Surgery Oral Medicine Oral Pathology and Oral Radiology · doi:10.1016/j.oooo.2015.07.017 · Cited by 34
RANKL signaling in bone physiology and cancer
Dougall, W. C. (2007) · Current Opinion in Supportive and Palliative Care · doi:10.1097/spc.0b013e3282f335be · Cited by 32
Effects of Escitalopram on Markers of Bone Turnover: A Randomized Clinical Trial
Diem, S. J., Joffe, H., Larson, J. C., Tsai, J. N., Guthrie, K. A., LaCroix, A. Z., Ensrud, K. E., Freeman, E. W., & Leder, B. Z. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-2288 · Cited by 30
Huang, D., Wang, Y., Lv, J., Yan, Y., Hu, Y., Liu, C., Zhang, F., Wang, J., & Hao, D. (2020) · PeerJ · doi:10.7717/peerj.9009 · Cited by 34
Spanish Menopause Society position statement
Mendoza, N., Abad, P., Baró, F., Hidalgo, M. J. C., Llaneza, P., Manubens, M., Quereda, F., & Sánchez‐Borrego, R. (2013) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0b013e31827b18c5 · Cited by 30
Interpretation of 41Ca data using compartmental modeling in post-menopausal women
Lee, W., Wastney, M. E., Jackson, G. S., Martin, B. R., & Weaver, C. M. (2010) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-010-4454-5 · Cited by 30
Current options for the management of postmenopausal osteoporosis
Lecart, M.-P., & Reginster, J. (2011) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2011.618123 · Cited by 35
Murahashi, Y., Teramoto, A., Jimbo, S., Okada, Y., Kamiya, T., Imamura, R., Takashima, H., Watanabe, K., Nagoya, S., & Yamashita, T. (2020) · The Knee · doi:10.1016/j.knee.2019.12.010 · Cited by 30
Tamaki, S., Kuroshima, S., Hayano, H., Nakajima, K., Kakehashi, H., Ishisaki, A., & Sawase, T. (2020) · Bone · doi:10.1016/j.bone.2020.115560 · Cited by 32
RANKL Inhibition: From Mice to Men (and Women)
Stolina, M., Kostenuik, P. J., Dougall, W. C., Fitzpatrick, L. A., & Zack, D. J. (2007) · Advances in experimental medicine and biology · doi:10.1007/978-0-387-72009-8_18 · Cited by 33
NCCN Task Force Report: Bone Health and Cancer Care
Theriault, R. L., Biermann, J. S., Brown, E., Brufsky, A., Demers, L. M., Grewal, R. K., Guise, T. A., Jackson, R. D., McEnery, K. W., Podoloff, D. A., et al. (2006) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2006.2002 · Cited by 30
Reginster, J. Y., Neuprez, A., Beaudart, C., Lecart, M. P., Sarlet, N., Bernard, D., Disteche, S., & Bruyere, O. (2014) · Drugs & Aging · doi:10.1007/s40266-014-0179-z · Cited by 29
Update on Denosumab Treatment in Postmenopausal Women with Osteoporosis
Min, Y. (2015) · Endocrinology and Metabolism · doi:10.3803/enm.2015.30.1.19 · Cited by 29
Jørgensen, L., Vik, A., Emaus, N., Brox, J. H., HANSEN, J. ‐., Mathiesen, E. B., & Vestergaard, P. (2009) · Osteoporosis International · doi:10.1007/s00198-009-1035-6 · Cited by 30
Iezaki, T., Fukasawa, K., Park, G., Horie, T., Kanayama, T., Ozaki, K., Onishi, Y., Takahata, Y., Nakamura, Y., Takarada, T., et al. (2016) · Molecular and Cellular Biology · doi:10.1128/mcb.01075-15 · Cited by 29
Effects of denosumab treatment in chronic liver disease patients with osteoporosis
Saeki, C., Saito, M., Oikawa, T., Nakano, M., Torisu, Y., Saruta, M., & Tsubota, A. (2020) · World Journal of Gastroenterology · doi:10.3748/wjg.v26.i33.4960 · Cited by 29
Effect of agents affecting bone homeostasis on short‐ and long‐term implant failure
Jung, J., Ryu, J., Shim, G., & Kwon, Y. (2023) · Clinical Oral Implants Research · doi:10.1111/clr.14144 · Cited by 32
Ramchand, S. K., Tsai, J. N., Lee, H., Sassana-Khadka, G., Jordan, M., Ryan, S. W., & Leder, B. Z. (2023) · Osteoporosis International · doi:10.1007/s00198-023-06932-2 · Cited by 30
Guañabens, N., Monegal, A., Muxí, Á., Martinez-Ferrer, A., Reyes, R., Caballería, J., del Río, L., Peris, P., Pons, F., & Parés, A. R. (2011) · Osteoporosis International · doi:10.1007/s00198-011-1756-1 · Cited by 33
Grey, A. B., Bolland, M. J., Mihov, B., Wong, S., Horne, A. M., Gamble, G. D., & Reid, I. R. (2013) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.2009 · Cited by 31
Iwamoto, J., Takeda, T., & Satō, Y. (2007) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.8.16.2743 · Cited by 29
RetractedGlucocorticoids and the risk of osteoporosis
Caplan, L., & Saag, K. G. (2008) · Expert Opinion on Drug Safety · doi:10.1517/14740330802648194 · Cited by 30
Osteoporosis Update From the 2010 Santa Fe Bone Symposium
Lewiecki, E. M., Bilezikian, J. P., Khosla, S., Marcus, R., McClung, M. R., Miller, P. D., Watts, N. B., & Maricic, M. J. (2011) · Journal of Clinical Densitometry · doi:10.1016/j.jocd.2010.12.001 · Cited by 28
Self-citationSmyth, B. J., & Ong, S. L. H. (2016) · Internal Medicine Journal · doi:10.1111/imj.13001 · Cited by 27
Pseudomyogenic hemangioendothelioma of bone treated with denosumab: a case report
Otani, S., Nakayama, R. T., Sekita, T., Hirozane, T., Asano, N., Nishimoto, K., Sasaki, A., Okita, H., Morioka, H., Nakamura, M., et al. (2019) · BMC Cancer · doi:10.1186/s12885-019-6072-8 · Cited by 27
The effect of osteoporosis treatment on bone mass
Appelman‐Dijkstra, N. M., Oei, H. L. D. W., Veldhuis‐Vlug, A. G., & Winter, E. M. (2022) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2022.101623 · Cited by 30
Mochizuki, T., Yano, K., Ikari, K., Hiroshima, R., & Okazaki, K. (2022) · Modern Rheumatology · doi:10.1093/mr/roac059 · Cited by 27
Zhang, H., Gu, J., Chao, A., Cheng, Q., Teng, D., Yu, J., Wang, B.-W., Huo, Y., Mao, L., Zhang, Q., et al. (2022) · Acta Pharmacologica Sinica · doi:10.1038/s41401-022-00954-y · Cited by 27
Ovariectomy increases vascular calcification via the OPG/RANKL cytokine signalling pathway
Choi, B. G., Vilahur, G., Cardoso, L., Fritton, J. C., Ibáñez, B., Zafar, M. U., Yadegar, D., Speidl, W. S., Schaffler, M. B., Fuster, V., et al. (2008) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.2008.01930.x · Cited by 27
Liu, M., Xiao, G. G., Rong, P., Zhang, Z., Dong, J., Zhao, H., Li, H., Li, Y., Pan, J., Liu, H., et al. (2012) · BMC Complementary and Alternative Medicine · doi:10.1186/1472-6882-12-67 · Cited by 27
Denosumab for the Treatment of Osteoporosis and Cancer-Related Conditions
Lewiecki, E. M., & Bilezikian, J. P. (2011) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2011.268 · Cited by 28
Self-citationMiossec, P. (2008) · Biologics · doi:10.2147/btt.s2338 · Cited by 35
Denosumab, a RANK Ligand Inhibitor, for Postmenopausal Women with Osteoporosis
Sutton, E., & Riche, D. M. (2012) · Annals of Pharmacotherapy · doi:10.1345/aph.1q543 · Cited by 33
Pathogenesis and Medical Management of Diabetic Charcot Neuroarthropathy
Mascarenhas, J. V., & Jude, E. B. (2013) · Medical Clinics of North America · doi:10.1016/j.mcna.2013.05.002 · Cited by 27
von Schwartzenberg, R. J., Elbelt, U., Ventz, M., Mai, K., Kienitz, T., Maurer, L., Rose, T., Rückert, J. C., Strasburger, C. J., & Spranger, J. (2015) · Endocrinology Diabetes and Metabolism Case Reports · doi:10.1530/edm-15-0082 · Cited by 27
Shao, J., Li, H., Zhang, X., Zhang, X., Li, Z.-Z., Jiao, G., & Sun, G. (2020) · Current Medical Science · doi:10.1007/s11596-020-2306-x · Cited by 29
Wang, Z., Huang, Z. D., Gan, J., Liu, N., Zhou, G., Shi, T., Wang, Z., Wang, R., Bao, N., Guo, T., et al. (2015) · Acta Biomaterialia · doi:10.1016/j.actbio.2015.06.024 · Cited by 28
Metadata
- Authors
- McClung, M. R., Lewiecki, E. M., Cohen, S. B., Bolognese, M. A., Woodson, G. C., Moffett, A. H., Peacock, M., Miller, P. D., Lederman, S. N., Chesnut, C. H., Lain, D., Kivitz, A. J., Holloway, D. L., Zhang, C., Peterson, M. C., & Bekker, P. J.
- Affiliations
- Providence Portland Medical Center (US)
- New Mexico Clinical Research & Osteoporosis Center (US)
- Radiant Research (United States) (US)
- National Institutes of Health (US)
- Lake OB/GYN Associates of Mid-Florida (US)
- Indiana University School of Medicine (US)
- Colorado Center for Bone Research (US)
- University of Washington Medical Center (US)
- Altoona Center for Clinical Research (US)
- Amgen (United States) (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2006-02-23
- Volume
- 354
- Issue
- 8
- Pages
- 821-831
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2482202957
- Cited by
- 1,228
- References
- 17
- Citations by year
- 2026: 28 · 2025: 32 · 2024: 32 · 2023: 26 · 2022: 38 · 2021: 38 · 2020: 56 · 2019: 39 · 2018: 50 · 2017: 46 · 2016: 46 · 2015: 70 · 2014: 39 · 2013: 65 · 2012: 77
- FWCI
- 118.60
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
- Keywords
- denosumab, RANKL inhibition, osteoporosis, postmenopausal women, osteopenia, bone mineral density, alendronate, bone turnover markers, C-terminal telopeptide, bone resorption, dose dependence, osteoclasts, monoclonal antibodies, lumbar spine, total hip, distal radius, treatment efficacy and safety, osteoporosis prevention
- MeSH terms
- Denosumab, Antibodies, Monoclonal, Bone Resorption, Carrier Proteins, Double-Blind Method, Female, Humans, Injections, Subcutaneous, Membrane Glycoproteins, Middle Aged, Biomarkers, Bone Density, Osteoporosis, Postmenopausal, Bone Remodeling, Alendronate, Bone Density Conservation Agents, RANK Ligand, Receptor Activator of Nuclear Factor-kappa B, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.